| abstract |
REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES a) AN INHIBITOR OF ANGIOTENSIN CONVERTING ENZYME (ACE) SUCH AS CAPTOPRIL, ENALAPRIL, ENALPRILAT, LISINOPRIL, RAMIPRIL, ZOFENOPRIL, TRILAPYLAPRIL, TEMPYLAPRIL, QUARNAPYLAPRIL, TEMPYLAPRIL, QUARRYLAPRIL, CERAMIC MOEXIPRIL, RENTIAPRIL, DUINAPRIL, SPIRAPRIL, CILAZAPRIL, PERINDOPRIL, FOSINOPRIL; b) A MATRIX METALOPROTEASE INHIBITOR SUCH AS 4- (4`-CHLOROBIPHENYL-4-IL) -4-HYDROXIMINO-BUTYRIC, 2- (4'-BROMOBIPHENYL-4-SULFONYLAMINE) -3-METHYL-BUTYRIC ACID OR A COMPOSED OF FORMULA I, WHERE A IS PHENYL, GROUP a; Y IS CH or N; R1 IS ALKYL, ARYL, HALO, OPTIONALLY SUBSTITUTED AMINO, ALCOXI; R2 IS CARBOXIALKYLKETONE OR OXYME, CARBOXIALKYLSULFONAMIDE. THE COMPOSITION HAS THE EFFECT OF DELAYING AND REVERSING THE PROCESS OF FIBROSIS, VENTRICULAR DILATATION, HEART FAILURE AND MAY BE USEFUL FOR THE TREATMENT OF CARDIOVASCULAR FIBROSIS, DILATED CARDIOMIOPATIA, CARDIAC VALVE FLEXIBILITY, CARDIAC VALVE FLEXIBILITY, CARDIAC VALVE FLEXIBILITY PULMONARY, ADULT RESPIRATORY FATIGUE SYNDROME, INFLAMMATORY DISORDERS, ANkylosing SPONDYLITIS, GLOMERULUM SCLEROSIS, PERITONEAL ADHERENCES |